FDA Clearance Tracker · P040037-S050
GORE VIABAHN ENDOPROSTHESIS, GORE VIABAHN ENDOPROSTHESIS WITH HEPARIN BIOACTIVE
Last checked: Nov 20, 2026Latest source record: Oct 18, 2013 (this decision)Source: openFDAMethods & limitations
Decided
Oct 18, 2013
Approved
Time to decision
172 days
Received Apr 29, 2013. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P040037-S050
- Device name
- GORE VIABAHN ENDOPROSTHESIS, GORE VIABAHN ENDOPROSTHESIS WITH HEPARIN BIOACTIVE
- Applicant
- W. L. Gore & Associates, Inc.
- Applicant location
- Flagstaff, AZ
- Received
- Apr 29, 2013
- Decided
- Oct 18, 2013
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P040037
Device type
- Device type
- STENT, SUPERFICIAL FEMORAL ARTERY (NIP)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE ADDITION OF A 25CM LENGTH FOR THE 5-8MM DIAMETER ENDOPROSTHESES. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME GORE VIABAHN ENDOPROSTHESIS AND GORE VIABAHN ENDOPROSTHESIS WITH HEPARIN BIOACTIVE SURFACE AND IS INDICATED FOR IMPROVING BLOOD FLOW IN PATIENTS WITH SYMPTOMATIC PERIPHERAL ARTERIAL DISEASE IN SUPERFICIAL FEMORAL ARTERY LESIONS UP TO 230 MM IN LENGTH WITH REFERENCE VESSEL DIAMETERS RANGING FROM 4.0 ¿ 7.5 MM. THE GORE VIABAHN ENDOPROSTHESIS AND GORE VIABAHN ENDOPROSTHESIS WITH HEPARIN BIOACTIVE SURFACE ARE ALSO INDICATED FOR IMPROVING BLOOD FLOW IN PATIENTS WITH SYMPTOMATIC PERIPHERAL ARTERIAL DISEASE IN ILIAC ARTERY LESIONS UP TO 80 MM IN LENGTH WITH REFERENCE VESSEL DIAMETERS RANGING FROM 4.0 ¿ 12 MM.
Source documents
Other decisions for W. L. Gore & Associates, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- GORE® VIABAHN® VBX Balloon Expandable EndoprosthesisPMA supplement
P160021-S051 · Decided Oct 8, 2026 · 244 days after receipt · Panel Track
Device type: Iliac covered stent, arterial (PRL) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.